WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > inVentiv Health Commercial
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
Legend Biotech Corporation | February 14, 2022
Legend Biotech Corporation, a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. Legend Biotech entered into the agreement with Janssen to d...
Bioclinica | September 10, 2020
Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...
Lygos Inc | July 26, 2022
Lygos Inc., a vertically integrated biotechnology provider of sustainable specialty ingredients, and Flexible Solutions International Inc. a developer and manufacturer of biodegradable products, today announced that FSI has filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on July 25, 2022 in connection with its proposed merger with Lygos. On April 18, 2022, Lygos and FSI announced a definitive merger agreement in an all-stock transaction ...
MedTech
N2 Biomedical | September 20, 2021
Precision Coating, a leading medical coatings service provider to interventional, orthopedic, and advanced surgical markets, is pleased to announce a merger with N2 Biomedical, a Bedford, MA-based company. N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies. ...
Whitepaper
Cell and Gene Therapy
Video
Medical, Industry Outlook
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE